S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma

Gene Therapy

Volumn 19, Issue 10, 2012, Pages 967-977

  Lee, K ^a,b   Yun, S T ^a   Yun, C O ^c   Ahn, B Y ^b   Jo, E C ^a  

^a Mogam Biotechnology Research Institute   (South Korea)

^b Korea University   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Conditionally replicative adenovirus; Epidermal growth factor receptor signaling; Non small cell lung carcinoma; S100A2 promoter

Indexed keywords

CETUXIMAB; CISPLATIN; CONDITIONALLY REPLICATING ADENOVIRUS; E1A PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG MEGADOSE; GENE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; S100A2 GENE; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOTACTIC FACTORS; CISPLATIN; GENE EXPRESSION; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; S100 PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA;

EID: 84867400153     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.168     Document Type: Article

References (45)

1. Ko D, Hawkins L, Yu DC Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 2005; 24: 7763-7774. (Pubitemid 41670678)
2. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976. (Pubitemid 41766784)
3. Toth K, Dhar D, Wold WS. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 2010; 10: 353-368.
4. Liu TC, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N, Kirn D. An E1B-19kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 2004; 9: 786-803. (Pubitemid 38878125)
5. Wolf S, Haase-Kohn C, Pietzsch J. S100A2 in cancerogenesis: a friend or a foe? Amino Acids 2010, E-pub ahead of print; doi:10.1007/s00726-010-0623-2.
6. Biankin AV, Kench JG, Colvin EK, Segara D, Scarlett CJ, Nguyen NQ et al. Expression ofS100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009; 137: 558-568.
7. Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M et al. S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res 2009; 15: 22-29.
8. 2+ binding protein S100A2 in laryngeal squamous-cell carcinoma. Int J Cancer 2000; 89: 345 - 349. (Pubitemid 30620287)
9. Ohuchida K, Mizumoto K, Miyasaka Y, Yu J, Cui L, Yamaguchi H et al. Over-expression ofS100A2 in pancreatic cancer correlates with progression and poor prognosis. J Pathol 2007; 213: 275-282. (Pubitemid 350074017)
10. Suzuki F, Oridate N, Homma A, Nakamaru Y, Nagahashi T, Yagi K et al. S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity. Oncol Rep 2005; 14: 1493-1498.
11. Wang H, Zhang Z, Li R, Ang KK, Zhang H, Caraway NP et al. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer 2005; 116: 285-290. (Pubitemid 40967267)
12. Kirschner RD, Sänger K, Müller GA, Engeland K. Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site. Nucleic Acids Res 2008; 36: 2969-2980. (Pubitemid 351737189)
13. van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem 2009; 284: 13804-13811.
14. van Dieck J, Brandt T, Teufel DP, Veprintsev DB, Joerger AC, Fersht AR. Molecular basis ofS100 proteins interacting with the p53 homologs p63 and p73. Oncogene 2010; 29: 2024-2035.
15. Stoll SW, Zhao X, Elder JT. EGF stimulates transcription of CaN19 (S100A2) in HaCaT keratinocytes. J Invest Dermatol 1998; 111: 1092 -1097. (Pubitemid 29115180)
16. Xia L, Stoll SW, Liebert M, Ethier SP, Carey T, Esclamado R et al. CaN19 expression in benign and malignant hyperplasias of the skin and oral mucosa: evidence for a role in regenerative differentiation. CancerRes 1997; 57: 3055-3062. (Pubitemid 27315060)
17. Deshpande R, Woods TL, Fu J, Zhang T, Stoll SW, Elder JT. Biochemical characterization ofS100A2 in human keratinocytes: subcellular localization, dimerization, and oxidative cross-linking. J Invest Dermatol 2000; 115: 477-485.
18. Kim J, Cho JY, Kim JH, Jung KC, Yun CO. Evaluation of E1B gene attenuated adenoviruses for cancer gene therapy. Cancer Gene Ther 2002; 9: 725-736. (Pubitemid 34971303)
19. Kim J, Kim JH, Choi KJ, Kim PH, Yun CO. E1A- and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther 2007; 18: 773-786. (Pubitemid 47502844)
20. Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR et al. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res 2010; 16: 541 -553.
21. Song X, Zhou Y, Jia R, Xu X, Wang H, Hu J et al. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101. Invest Ophthalmol Vis Sci 2010; 51: 2626-2635.
22. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637-4642. (Pubitemid 23304392)
23. ReuterCW, Morgan MA, EckardtA.Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007; 96: 408-416. (Pubitemid 46215210)
24. Feng G, Xu X, Youssef EM, Lotan R. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res 2001; 61: 7999-8004. (Pubitemid 33049393)
25. Zhang X, Hunt JL, Shin DM, Chen ZG. Down-regulation ofS100A2 in lymph node metastases of head and neck cancer. Head Neck 2007; 29: 236-243. (Pubitemid 46339320)
26. Lee SW, Tomasetto C, Sager R. Positive selection of candidate tumor-suppressor genes by subtractive hybridization. Proc Natl Acad Sci USA 1991; 88: 2825-2829. (Pubitemid 21916512)
27. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ et al. Gastric cancers overexpress S100A calcium-binding proteins. CancerRes 2002; 62: 6823-6826. (Pubitemid 35424067)
28. Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002; 21: 7749-7763. (Pubitemid 35398821)
29. Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, Simm A. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 2007; 43: 1935-1943. (Pubitemid 47284868)
30. Shimada A, Kano J, Ishiyama T, Okubo C, Iijima T, Morishita Y et al. Establishment of an immortalized cell linefrom a precancerous lesion oflung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development. Cancer Sci 2005; 96: 668-675. (Pubitemid 41723543)
31. Smith SL, Gugger M, Hoban P, Ratschiller D, Watson SG, Field JK et al. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. BrJCancer2004; 91: 1515-1524. (Pubitemid 39486357)
32. Wicki R, Franz C, Scholl FA, Heizmann CW, Schäfer BW. Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium 1997; 22: 243-254. (Pubitemid 27490305)
33. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N et al. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008; 110: 317-326. (Pubitemid 351793880)
34. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10: 8472-8478. (Pubitemid 40053412)
35. Matsubara D, Niki T, Ishikawa S, Goto A, Ohara E, Yokomizo T et al. Differential expression ofS100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci 2005; 96: 844-857. (Pubitemid 43056122)
36. Rehman I, Cross SS, Catto JW, Leiblich A, Mukherjee A, Azzouzi AR et al. Promoter hyper-methylation ofcalcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate 2005; 65: 322-330. (Pubitemid 41759964)
37. Vardimon L, Neumann R, Kuhlmann I, Sutter D, Doerfler W. DNA methylation and viral gene expression in adenovirus-transformed and -infected cells. Nucleic Acids Res 1980; 8: 2461 -2473. (Pubitemid 11233248)
38. 2+-binding S100 proteins in epithelial tumours of the skin. Virchows Arch 1998; 432: 53-59. (Pubitemid 28065839)
39. Chung I, Akita R,Vandlen R,Toomre D, Schlessinger J, Mellman I. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 2010; 464: 783-788.
40. Macdonald JL, Pike LJ. Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system. Proc Nat AcadSci USA 2008; 105: 112-117.
41. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009; 373: 1525-1531.
42. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.JClin Oncol 2010; 28: 911 -917.
43. Morgensztern D, Govindan R. Is there a role for cetuximab in non-small cell lung cancer? Clin Cancer Res 2007; 13: 4602s-4605s. (Pubitemid 47219732)
44. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010; 316: 1083-1100.
45. Lee K, Yun ST, Kim YG, Yun Y, Jo EC Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice. Hepatology2006; 43: 1063-1073. (Pubitemid 43724630)